(Adds detail from EMA statement, background)
Dec 16 (Reuters) - The European Union's drug regulator on
Thursday approved a COVID-19 treatment from British-U.S. duo GSK
GSK.L and Vir Biotechnology VIR.O and another from Swedish
drugmaker Sobi SOBIV.ST , as the bloc builds its defences
against Omicron.
The approval by the European Medicines Agency (EMA) of
GSK-Vir's antibody drug sotrovimab and Sobi's arthritis drug
Kineret come as governments struggle with soaring infections
and worry about the swiftly-spreading Omicron variant of the
coronavirus.
The European Union's public health body warned on Wednesday
that there was a "very high" risk Omicron would become dominant
in Europe by early next year. urn:newsml:reuters.com:*:nL1N2T01DJ
EMA's human medicines committee recommended using Kineret to
treat COVID-19 in adults with pneumonia requiring oxygen support
and those who were at risk of developing severe respiratory
failure.
GSK-Vir's sotrovimab, branded Xevudy, was recommended for
treating adults and adolescents who did not require oxygen
support but were at a higher risk their disease would worsen.
Final and formal approvals are up to the European
Commission, which typically endorses EMA recommendations.
<^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
Omicron set to be Europe's dominant variant by early 2022 - ECDC
urn:newsml:reuters.com:*:nL1N2T01DJ
COVID SCIENCE-Omicron thrives in airways, not lungs; new data on
asymptomatic cases urn:newsml:reuters.com:*:nL1N2T02CQ
FACTBOX-Front runners in development of antibody drugs against
COVID-19 urn:newsml:reuters.com:*:nL8N2R81NW
FACTBOX-What COVID-19 vaccine and drug makers have to say about
Omicron urn:newsml:reuters.com:*:nL4N2SN31Z
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^>
(Reporting by Pushkala Aripaka and Amna Karimi in Bengaluru;
Editing by Edmund Blair)
((Amna.Karimi@thomsonreuters.com;))